US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Enlivex Therapeutics Ltd.

0.9289

-0.0301-3.14%

Post-market: 0.94480.0159+1.71%19:48 EST

Volume:922.63K

Turnover:861.85K

Market Cap:219.22M

PE:-1.72

High:0.9998

Open:0.9900

Low:0.9000

Close:0.9590

52wk High:2.10

52wk Low:0.8313

Shares:236.00M

Float Shares:235.00M

Volume Ratio:0.87

T/O Rate:0.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5394

EPS(LYR):-0.7319

ROE:-57.64%

ROA:-36.02%

PB:12.54

PE(LYR):-1.27

Loading ...

Overview Company News Filings

Enlivex Therapeutics Raises $212 Million in Private Placement

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

Press Release: Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play

Enlivex Reports Six-Month Data Showing Sustained Pain Relief With Allocetra in Knee Osteoarthritis

Enlivex Therapeutics Reports Positive Phase IIa Allocetra Results in Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders

Enlivex Therapeutics CEO issues letter to shareholders on Allocetra results

Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026

Enlivex Therapeutics Ltd. Secures Israeli Patent for Allocetra™ in Osteoarthritis Treatment

Enlivex Therapeutics Ltd reports results for the quarter ended June 30 - Earnings Summary

Enlivex Therapeutics Reports Net Loss of $5.32 Million, EPS Declines to $(0.22)

Enlivex Therapeutics Ltd expected to post a loss of 16 cents a share - Earnings Preview

Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Enlivex Therapeutics Announces Positive Results from Phase I/II Trial of Allocetra™ for Knee Osteoarthritis Treatment

Enlivex Therapeutics to Present Promising 3-Month Topline Data from Phase IIa Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis

Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025

Enlivex Therapeutics Ltd. Reports No Revenue, Increased Loss for Q1 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENLV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENLV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENLV\",,,,,undefined,":{"symbol":"ENLV","market":"US","secType":"STK","nameCN":"Enlivex Therapeutics Ltd.","latestPrice":0.9289,"timestamp":1765573200000,"preClose":0.959,"halted":0,"volume":922629,"hourTrading":{"tag":"盘后","latestPrice":0.9448,"preClose":0.9289,"latestTime":"19:48 EST","volume":1456,"amount":1373.9121,"timestamp":1765586900555},"delay":0,"floatShares":235000000,"shares":236000000,"eps":-0.539407,"marketStatus":"Market Closed","change":-0.0301,"latestTime":"12-12 16:00:00 EST","open":0.99,"high":0.9998,"low":0.9,"amount":861854.83728744,"amplitude":0.104067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.539407,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1406779200000,"exchange":"NASDAQ","adjPreClose":0.959,"preHourTrading":{"tag":"盘前","latestPrice":0.98,"preClose":0.959,"latestTime":"08:57 EST","volume":4998,"amount":4916.91974508,"timestamp":1765547857384},"postHourTrading":{"tag":"盘后","latestPrice":0.9448,"preClose":0.9289,"latestTime":"19:48 EST","volume":1456,"amount":1373.9121,"timestamp":1765586900555},"volumeRatio":0.8726763871188041,"impliedVol":1.3007,"impliedVolPercentile":0.368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENLV\",,,,,undefined,":{"symbol":"ENLV","floatShares":235000000,"roa":"-36.02%","roe":"-57.64%","lyrEps":-0.73189,"volumeRatio":0.8726763871188041,"shares":236000000,"dividePrice":0,"high":0.9998,"amplitude":0.104067,"preClose":0.959,"low":0.9,"week52Low":0.8313,"pbRate":"12.54","week52High":2.1,"institutionHeld":0,"latestPrice":0.9289,"eps":-0.539407,"divideRate":0,"volume":922629,"delay":0,"ttmEps":-0.539407,"open":0.99,"prevYearClose":1.17,"prevWeekClose":1.21,"prevMonthClose":0.9699,"prevQuarterClose":1.04,"fiveDayClose":1.21,"twentyDayClose":0.9901,"sixtyDayClose":1.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENLV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-29","symbol":"ENLV","fiscalQuarterEnding":"2025/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1756440000000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2025-05-30","symbol":"ENLV","fiscalQuarterEnding":"2025/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1748577600000,"reportTimeType":"post","actualEps":-0.15},{"date":"2023-09-11","symbol":"ENLV","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1694419200000,"name":null,"time":"Pre-Market","dateTimestamp":1694404800000,"actualEps":null},{"market":"US","date":"2023-06-26","symbol":"ENLV","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1687752000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-04-04","symbol":"ENLV","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1680580800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENLV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENLV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1764046800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENLV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENLV","date":"2025-12-12","current":-1.722076,"percent":0.610252,"low":-42.250582,"twenty":-8.41304,"median":-2.297891,"eighty":-1.390368,"high":-0.807503,"avg":-5.391853,"sd":6.729854,"marketCap":23296826},"quantilePoints":[{"date":"2020-12-18","current":-17.757371,"twenty":-28.589355,"median":-11.575956,"eighty":-9.343904,"marketCap":156744311},{"date":"2020-12-24","current":-17.023595,"twenty":-28.468598,"median":-11.624687,"eighty":-9.347491,"marketCap":150267273},{"date":"2020-12-31","current":-13.746064,"twenty":-28.173958,"median":-11.643303,"eighty":-9.35412,"marketCap":121336505},{"date":"2021-01-08","current":-15.931538,"twenty":-27.574936,"median":-11.920309,"eighty":-9.364578,"marketCap":140627683},{"date":"2021-01-15","current":-17.336289,"twenty":-27.118197,"median":-12.046285,"eighty":-9.382558,"marketCap":153027427},{"date":"2021-01-22","current":-19.914422,"twenty":-27.024496,"median":-12.223595,"eighty":-9.409419,"marketCap":175784604},{"date":"2021-01-29","current":-19.749157,"twenty":-26.84195,"median":-12.469564,"eighty":-9.421961,"marketCap":174325811},{"date":"2021-02-05","current":-31.400334,"twenty":-26.84195,"median":-12.529307,"eighty":-9.45474,"marketCap":277170746},{"date":"2021-02-12","current":-38.255446,"twenty":-28.281254,"median":-12.60197,"eighty":-9.456211,"marketCap":337680820},{"date":"2021-02-19","current":-37.135481,"twenty":-29.264756,"median":-12.640235,"eighty":-9.462094,"marketCap":327794891},{"date":"2021-02-26","current":-31.703043,"twenty":-30.554331,"median":-12.659911,"eighty":-9.472613,"marketCap":279842763},{"date":"2021-03-05","current":-26.934109,"twenty":-30.554331,"median":-12.982325,"eighty":-9.472613,"marketCap":237747383},{"date":"2021-03-12","current":-29.73593,"twenty":-30.417505,"median":-13.33841,"eighty":-9.474579,"marketCap":262479052},{"date":"2021-03-19","current":-27.939384,"twenty":-30.246813,"median":-13.55039,"eighty":-9.480014,"marketCap":246620943},{"date":"2021-03-26","current":-22.776896,"twenty":-30.090084,"median":-13.669721,"eighty":-9.490486,"marketCap":201051663},{"date":"2021-04-01","current":-23.313795,"twenty":-29.806761,"median":-13.754217,"eighty":-9.496445,"marketCap":205790868},{"date":"2021-04-09","current":-24.201743,"twenty":-29.62029,"median":-13.925431,"eighty":-9.506274,"marketCap":213628784},{"date":"2021-04-16","current":-22.652996,"twenty":-29.444186,"median":-14.142214,"eighty":-9.508359,"marketCap":199958000},{"date":"2021-04-23","current":-21.22815,"twenty":-29.293282,"median":-14.496146,"eighty":-9.514357,"marketCap":187380879},{"date":"2021-04-30","current":-17.711306,"twenty":-29.261736,"median":-15.17285,"eighty":-9.526996,"marketCap":209418477},{"date":"2021-05-07","current":-15.543838,"twenty":-28.831462,"median":-15.324978,"eighty":-9.541239,"marketCap":183790342},{"date":"2021-05-14","current":-14.537514,"twenty":-28.618492,"median":-15.17285,"eighty":-9.545905,"marketCap":171891565},{"date":"2021-05-21","current":-15.404501,"twenty":-28.589355,"median":-15.213615,"eighty":-9.550629,"marketCap":182142819},{"date":"2021-05-28","current":-12.053791,"twenty":-28.428574,"median":-15.07164,"eighty":-9.551697,"marketCap":171525449},{"date":"2021-06-04","current":-12.529768,"twenty":-28.19339,"median":-15.033591,"eighty":-9.558436,"marketCap":178298599},{"date":"2021-06-11","current":-12.285348,"twenty":-27.988944,"median":-14.630405,"eighty":-9.583805,"marketCap":174820495},{"date":"2021-06-18","current":-12.040927,"twenty":-27.886995,"median":-14.552996,"eighty":-9.608447,"marketCap":171342390},{"date":"2021-06-25","current":-11.938013,"twenty":-27.607099,"median":-14.369688,"eighty":-9.620266,"marketCap":169877926},{"date":"2021-07-02","current":-11.449172,"twenty":-27.273056,"median":-14.210669,"eighty":-9.642686,"marketCap":162921717},{"date":"2021-07-09","current":-10.522947,"twenty":-27.118197,"median":-14.096646,"eighty":-9.664912,"marketCap":149741533},{"date":"2021-07-16","current":-9.596722,"twenty":-27.015919,"median":-13.794982,"eighty":-9.664912,"marketCap":136561350},{"date":"2021-07-23","current":-9.570993,"twenty":-26.94655,"median":-13.721605,"eighty":-9.636251,"marketCap":136195233},{"date":"2021-07-30","current":-9.776821,"twenty":-26.925815,"median":-13.631921,"eighty":-9.628153,"marketCap":139124163},{"date":"2021-08-06","current":-10.589086,"twenty":-26.906399,"median":-13.428095,"eighty":-9.643412,"marketCap":151392158},{"date":"2021-08-13","current":-13.021886,"twenty":-26.825976,"median":-13.329925,"eighty":-9.664912,"marketCap":186173911},{"date":"2021-08-20","current":-13.226754,"twenty":-26.712777,"median":-13.317861,"eighty":-9.682201,"marketCap":189102901},{"date":"2021-08-27","current":-15.326645,"twenty":-26.670636,"median":-13.371023,"eighty":-9.692107,"marketCap":219125046},{"date":"2021-09-03","current":-15.00654,"twenty":-26.583373,"median":-13.517778,"eighty":-9.704975,"marketCap":214548499},{"date":"2021-09-10","current":-14.507175,"twenty":-26.507376,"median":-13.595792,"eighty":-9.714953,"marketCap":207409087},{"date":"2021-09-17","current":-14.91691,"twenty":-26.456266,"median":-13.697145,"eighty":-9.724684,"marketCap":213267066},{"date":"2021-09-24","current":-14.238287,"twenty":-26.422703,"median":-13.754217,"eighty":-9.741035,"marketCap":203564788},{"date":"2021-10-01","current":-12.154068,"twenty":-26.305176,"median":-13.713314,"eighty":-9.77839,"marketCap":173766711},{"date":"2021-10-08","current":-12.166875,"twenty":-26.15391,"median":-13.637109,"eighty":-9.784665,"marketCap":173949816},{"date":"2021-10-15","current":-11.885116,"twenty":-25.995727,"median":-13.55039,"eighty":-9.786233,"marketCap":169921504},{"date":"2021-10-22","current":-10.822115,"twenty":-25.825302,"median":-13.476436,"eighty":-9.79287,"marketCap":154723784},{"date":"2021-10-29","current":-10.553163,"twenty":-25.732176,"median":-13.329925,"eighty":-9.797932,"marketCap":150878577},{"date":"2021-11-05","current":-11.167911,"twenty":-25.699442,"median":-13.233156,"eighty":-9.814162,"marketCap":159667621},{"date":"2021-11-12","current":-10.578778,"twenty":-25.692352,"median":-13.021886,"eighty":-9.824129,"marketCap":151244787},{"date":"2021-11-19","current":-9.367411,"twenty":-25.673789,"median":-12.93377,"eighty":-9.824129,"marketCap":146094140},{"date":"2021-11-26","current":-8.897277,"twenty":-25.599535,"median":-12.742452,"eighty":-9.792506,"marketCap":138761937},{"date":"2021-12-03","current":-7.63967,"twenty":-25.590971,"median":-12.6477,"eighty":-9.732088,"marketCap":119148295},{"date":"2021-12-10","current":-7.81597,"twenty":-25.590971,"median":-12.629123,"eighty":-9.687087,"marketCap":121897871},{"date":"2021-12-17","current":-7.369343,"twenty":-25.558271,"median":-12.60197,"eighty":-9.623379,"marketCap":114932278},{"date":"2021-12-23","current":-7.28707,"twenty":-25.472761,"median":-12.542632,"eighty":-9.591576,"marketCap":113649143},{"date":"2021-12-31","current":-7.345837,"twenty":-25.399668,"median":-12.526145,"eighty":-9.556843,"marketCap":114565668},{"date":"2022-01-07","current":-7.099017,"twenty":-25.345397,"median":-12.520418,"eighty":-9.541239,"marketCap":110716262},{"date":"2022-01-14","current":-6.89921,"twenty":-25.261359,"median":-12.494045,"eighty":-9.506274,"marketCap":107600076},{"date":"2022-01-21","current":-6.464336,"twenty":-25.089038,"median":-12.473937,"eighty":-9.47784,"marketCap":100817788},{"date":"2022-01-28","current":-6.052969,"twenty":-24.79081,"median":-12.388261,"eighty":-9.459152,"marketCap":94402111},{"date":"2022-02-04","current":-5.817903,"twenty":-24.524483,"median":-12.339773,"eighty":-9.391964,"marketCap":90736009},{"date":"2022-02-11","current":-6.005956,"twenty":-24.41624,"median":-12.285348,"eighty":-9.347491,"marketCap":93668890},{"date":"2022-02-18","current":-6.147331,"twenty":-24.282838,"median":-12.223595,"eighty":-9.296205,"marketCap":95873781},{"date":"2022-02-25","current":-6.029792,"twenty":-24.185223,"median":-12.179682,"eighty":-9.24788,"marketCap":94040630},{"date":"2022-03-04","current":-5.81822,"twenty":-24.147801,"median":-12.154068,"eighty":-9.057963,"marketCap":90740959},{"date":"2022-03-11","current":-6.241363,"twenty":-23.991611,"median":-12.073087,"eighty":-8.920086,"marketCap":97340302},{"date":"2022-03-18","current":-6.300133,"twenty":-23.753921,"median":-12.040927,"eighty":-8.750736,"marketCap":98256877},{"date":"2022-03-25","current":-6.382411,"twenty":-23.656584,"median":-11.969729,"eighty":-8.684531,"marketCap":99540083},{"date":"2022-04-01","current":-6.717399,"twenty":-23.573984,"median":-11.938013,"eighty":-8.511768,"marketCap":104764562},{"date":"2022-04-08","current":-9.544232,"twenty":-23.553334,"median":-11.922729,"eighty":-8.511768,"marketCap":148851836},{"date":"2022-04-14","current":-8.686191,"twenty":-23.540944,"median":-11.894412,"eighty":-8.34487,"marketCap":135469836},{"date":"2022-04-22","current":-7.851659,"twenty":-23.495514,"median":-11.860828,"eighty":-8.255074,"marketCap":122454466},{"date":"2022-04-29","current":-7.225933,"twenty":-23.289015,"median":-11.77721,"eighty":-8.169363,"marketCap":104544799},{"date":"2022-05-06","current":-5.435324,"twenty":-23.166112,"median":-11.645343,"eighty":-8.041478,"marketCap":78638267},{"date":"2022-05-13","current":-5.435324,"twenty":-23.069985,"median":-11.624687,"eighty":-7.969071,"marketCap":78638267},{"date":"2022-05-20","current":-5.11784,"twenty":-23.032956,"median":-11.577814,"eighty":-7.881398,"marketCap":74044910},{"date":"2022-05-27","current":-4.448909,"twenty":-22.876016,"median":-11.551542,"eighty":-7.852492,"marketCap":86722575},{"date":"2022-06-03","current":-4.863637,"twenty":-22.776896,"median":-11.537249,"eighty":-7.827724,"marketCap":94806883},{"date":"2022-06-10","current":-4.010616,"twenty":-22.652996,"median":-11.500899,"eighty":-7.81597,"marketCap":78178931},{"date":"2022-06-17","current":-3.760836,"twenty":-22.529097,"median":-11.477248,"eighty":-7.72912,"marketCap":73309973},{"date":"2022-06-24","current":-4.373503,"twenty":-22.446497,"median":-11.464459,"eighty":-7.681738,"marketCap":85252701},{"date":"2022-07-01","current":-4.203842,"twenty":-22.376287,"median":-11.449172,"eighty":-7.640252,"marketCap":81945484},{"date":"2022-07-08","current":-5.278366,"twenty":-22.305556,"median":-11.438627,"eighty":-7.613627,"marketCap":102891191},{"date":"2022-07-15","current":-4.627996,"twenty":-22.101984,"median":-11.428444,"eighty":-7.55138,"marketCap":90213526},{"date":"2022-07-22","current":-3.987052,"twenty":-21.967418,"median":-11.387691,"eighty":-7.503446,"marketCap":77719596},{"date":"2022-07-29","current":-4.005903,"twenty":-21.913728,"median":-11.301792,"eighty":-7.431035,"marketCap":78087064},{"date":"2022-08-05","current":-4.863637,"twenty":-21.888948,"median":-11.237452,"eighty":-7.399356,"marketCap":94806883},{"date":"2022-08-12","current":-4.797658,"twenty":-21.862089,"median":-11.216095,"eighty":-7.353705,"marketCap":93520743},{"date":"2022-08-19","current":-4.825935,"twenty":-21.677916,"median":-11.173407,"eighty":-7.324758,"marketCap":94071946},{"date":"2022-08-26","current":-4.004998,"twenty":-21.508695,"median":-11.14152,"eighty":-7.292354,"marketCap":105323427},{"date":"2022-09-02","current":-3.606595,"twenty":-21.463334,"median":-11.116916,"eighty":-7.270111,"marketCap":94846228},{"date":"2022-09-09","current":-3.424867,"twenty":-21.405349,"median":-11.08117,"eighty":-7.237681,"marketCap":90067154},{"date":"2022-09-16","current":-3.368951,"twenty":-21.286149,"median":-11.075135,"eighty":-7.177095,"marketCap":88596670},{"date":"2022-09-23","current":-2.872695,"twenty":-21.208634,"median":-11.058612,"eighty":-7.086181,"marketCap":75546123},{"date":"2022-09-30","current":-2.970548,"twenty":-21.177073,"median":-11.028796,"eighty":-7.033351,"marketCap":78119471},{"date":"2022-10-07","current":-2.98112,"twenty":-21.121105,"median":-11.001417,"eighty":-6.964376,"marketCap":78397482},{"date":"2022-10-14","current":-2.918138,"twenty":-21.020838,"median":-10.97259,"eighty":-6.897942,"marketCap":76741198},{"date":"2022-10-21","current":-3.042212,"twenty":-20.985326,"median":-10.924573,"eighty":-6.845568,"marketCap":80004079},{"date":"2022-10-28","current":-3.019608,"twenty":-20.977642,"median":-10.867286,"eighty":-6.810107,"marketCap":79409656},{"date":"2022-11-04","current":-3.009111,"twenty":-20.903933,"median":-10.84773,"eighty":-6.664507,"marketCap":79133609},{"date":"2022-11-11","current":-3.219049,"twenty":-20.756177,"median":-10.82938,"eighty":-6.546173,"marketCap":84654559},{"date":"2022-11-18","current":-3.358938,"twenty":-20.668581,"median":-10.726981,"eighty":-6.478794,"marketCap":88333351},{"date":"2022-11-25","current":-3.261037,"twenty":-20.630862,"median":-10.714226,"eighty":-6.373008,"marketCap":85758748},{"date":"2022-12-02","current":-2.870497,"twenty":-20.600195,"median":-10.688457,"eighty":-6.299858,"marketCap":82116306},{"date":"2022-12-09","current":-2.773956,"twenty":-20.530642,"median":-10.652221,"eighty":-6.276625,"marketCap":79354547},{"date":"2022-12-16","current":-2.568001,"twenty":-20.466533,"median":-10.603143,"eighty":-6.251552,"marketCap":73462794},{"date":"2022-12-23","current":-2.50364,"twenty":-20.27992,"median":-10.586676,"eighty":-6.168488,"marketCap":71621621},{"date":"2022-12-30","current":-2.534211,"twenty":-20.15537,"median":-10.584284,"eighty":-6.147331,"marketCap":72496179},{"date":"2023-01-06","current":-2.735339,"twenty":-20.094824,"median":-10.578778,"eighty":-6.048334,"marketCap":78249844},{"date":"2023-01-13","current":-2.812057,"twenty":-20.035005,"median":-10.550787,"eighty":-6.001255,"marketCap":80444521},{"date":"2023-01-20","current":-2.670978,"twenty":-19.978946,"median":-10.539281,"eighty":-5.966125,"marketCap":76408671},{"date":"2023-01-27","current":-2.844753,"twenty":-19.92865,"median":-10.527112,"eighty":-5.924006,"marketCap":81379837},{"date":"2023-02-03","current":-2.83188,"twenty":-19.914681,"median":-10.518845,"eighty":-5.829586,"marketCap":81011603},{"date":"2023-02-10","current":-2.7997,"twenty":-19.912392,"median":-10.5062,"eighty":-5.803799,"marketCap":80091016},{"date":"2023-02-17","current":-2.638798,"twenty":-19.895957,"median":-10.459125,"eighty":-5.435324,"marketCap":75488084},{"date":"2023-02-24","current":-2.471459,"twenty":-19.873903,"median":-10.442134,"eighty":-5.343888,"marketCap":70701035},{"date":"2023-03-03","current":-2.53582,"twenty":-19.846258,"median":-10.408105,"eighty":-5.257533,"marketCap":72542208},{"date":"2023-03-10","current":-2.336301,"twenty":-19.83179,"median":-10.356918,"eighty":-5.11784,"marketCap":66834572},{"date":"2023-03-17","current":-2.291249,"twenty":-19.827342,"median":-10.280555,"eighty":-4.987615,"marketCap":65545751},{"date":"2023-03-24","current":-2.297685,"twenty":-19.792064,"median":-10.24585,"eighty":-4.882489,"marketCap":65729868},{"date":"2023-03-31","current":-2.342737,"twenty":-19.702524,"median":-10.187527,"eighty":-4.844757,"marketCap":67018689},{"date":"2023-04-06","current":-1.686256,"twenty":-19.632558,"median":-10.178515,"eighty":-4.82782,"marketCap":48238727},{"date":"2023-04-14","current":-1.761523,"twenty":-19.623856,"median":-10.152662,"eighty":-4.778806,"marketCap":54712900},{"date":"2023-04-21","current":-1.74373,"twenty":-19.588234,"median":-10.098427,"eighty":-4.644962,"marketCap":54160244},{"date":"2023-04-28","current":-1.714074,"twenty":-19.576906,"median":-10.035554,"eighty":-4.518659,"marketCap":53239152},{"date":"2023-05-05","current":-1.654764,"twenty":-19.545187,"median":-10.025454,"eighty":-4.450794,"marketCap":51396967},{"date":"2023-05-12","current":-1.672557,"twenty":-19.516872,"median":-10.012699,"eighty":-4.39047,"marketCap":51949622},{"date":"2023-05-19","current":-1.589522,"twenty":-19.460547,"median":-9.999892,"eighty":-4.266051,"marketCap":49370563},{"date":"2023-05-26","current":-1.57766,"twenty":-19.427915,"median":-9.975789,"eighty":-4.215152,"marketCap":49002126},{"date":"2023-06-02","current":-1.506488,"twenty":-19.352412,"median":-9.936043,"eighty":-4.127494,"marketCap":46791504},{"date":"2023-06-09","current":-1.601384,"twenty":-19.277733,"median":-9.905463,"eighty":-4.005903,"marketCap":49739000},{"date":"2023-06-16","current":-1.666626,"twenty":-19.224922,"median":-9.888874,"eighty":-3.984029,"marketCap":51765404},{"date":"2023-06-22","current":-1.685692,"twenty":-19.216442,"median":-9.879735,"eighty":-3.907876,"marketCap":50660093},{"date":"2023-06-30","current":-1.590794,"twenty":-19.208775,"median":-9.865308,"eighty":-3.854893,"marketCap":47808124},{"date":"2023-07-07","current":-1.507393,"twenty":-19.20072,"median":-9.828261,"eighty":-3.760836,"marketCap":45301679},{"date":"2023-07-14","current":-1.427081,"twenty":-19.193508,"median":-9.794325,"eighty":-3.690469,"marketCap":42888065},{"date":"2023-07-21","current":-1.507393,"twenty":-19.088098,"median":-9.784665,"eighty":-3.638302,"marketCap":45301679},{"date":"2023-07-28","current":-1.47082,"twenty":-18.913767,"median":-9.732088,"eighty":-3.592616,"marketCap":44202556},{"date":"2023-08-04","current":-1.834818,"twenty":-18.866187,"median":-9.706309,"eighty":-3.410888,"marketCap":55141798},{"date":"2023-08-11","current":-1.587705,"twenty":-18.752044,"median":-9.678943,"eighty":-3.358938,"marketCap":47715293},{"date":"2023-08-18","current":-1.54446,"twenty":-18.637901,"median":-9.629347,"eighty":-3.268035,"marketCap":46415655},{"date":"2023-08-25","current":-1.482682,"twenty":-18.599214,"median":-9.603002,"eighty":-3.22916,"marketCap":44559028},{"date":"2023-09-01","current":-1.476504,"twenty":-18.588983,"median":-9.583858,"eighty":-3.170064,"marketCap":44373366},{"date":"2023-09-08","current":-1.599351,"twenty":-18.484624,"median":-9.566961,"eighty":-3.120328,"marketCap":43073727},{"date":"2023-09-15","current":-1.305186,"twenty":-18.093277,"median":-9.551697,"eighty":-3.053757,"marketCap":35151268},{"date":"2023-09-22","current":-1.084202,"twenty":-17.998272,"median":-9.545293,"eighty":-3.017509,"marketCap":29199731},{"date":"2023-09-29","current":-1.035862,"twenty":-17.946983,"median":-9.529781,"eighty":-3.000867,"marketCap":27897832},{"date":"2023-10-06","current":-1.069424,"twenty":-17.910179,"median":-9.508359,"eighty":-2.980403,"marketCap":28801722},{"date":"2023-10-13","current":-0.92537,"twenty":-17.786722,"median":-9.490486,"eighty":-2.958726,"marketCap":24922063},{"date":"2023-10-20","current":-0.994427,"twenty":-17.748788,"median":-9.473596,"eighty":-2.934164,"marketCap":26781919},{"date":"2023-10-27","current":-0.904653,"twenty":-17.745767,"median":-9.472613,"eighty":-2.925793,"marketCap":24364107},{"date":"2023-11-03","current":-0.97371,"twenty":-17.742028,"median":-9.45474,"eighty":-2.910919,"marketCap":26223962},{"date":"2023-11-10","current":-1.208506,"twenty":-17.735112,"median":-9.411049,"eighty":-2.890849,"marketCap":32547471},{"date":"2023-11-17","current":-1.191425,"twenty":-17.657513,"median":-9.365376,"eighty":-2.873386,"marketCap":32361485},{"date":"2023-11-24","current":-1.321523,"twenty":-17.442343,"median":-9.347503,"eighty":-2.851189,"marketCap":35895211},{"date":"2023-12-01","current":-1.259898,"twenty":-17.38233,"median":-9.315219,"eighty":-2.83188,"marketCap":34221341},{"date":"2023-12-08","current":-1.170883,"twenty":-17.336289,"median":-9.293885,"eighty":-2.806136,"marketCap":31803529},{"date":"2023-12-15","current":-0.986007,"twenty":-17.300799,"median":-9.252569,"eighty":-2.773956,"marketCap":26781919},{"date":"2023-12-22","current":-1.561178,"twenty":-17.246848,"median":-9.139522,"eighty":-2.767519,"marketCap":42404705},{"date":"2023-12-29","current":-1.766596,"twenty":-17.221185,"median":-9.061538,"eighty":-2.760774,"marketCap":47984271},{"date":"2024-01-05","current":-2.506101,"twenty":-17.167981,"median":-8.982854,"eighty":-2.752073,"marketCap":68070711},{"date":"2024-01-12","current":-2.067876,"twenty":-17.020028,"median":-8.925788,"eighty":-2.723754,"marketCap":56167636},{"date":"2024-01-19","current":-1.828221,"twenty":-17.00576,"median":-8.789589,"eighty":-2.677414,"marketCap":49658141},{"date":"2024-01-26","current":-1.985708,"twenty":-16.968174,"median":-8.734252,"eighty":-2.645234,"marketCap":53935809},{"date":"2024-02-02","current":-1.882999,"twenty":-16.939654,"median":-8.685954,"eighty":-2.625925,"marketCap":51146026},{"date":"2024-02-09","current":-1.807679,"twenty":-16.938913,"median":-8.684531,"eighty":-2.593745,"marketCap":49100185},{"date":"2024-02-16","current":-2.197974,"twenty":-16.925758,"median":-8.618237,"eighty":-2.567726,"marketCap":59701361},{"date":"2024-02-23","current":-2.115806,"twenty":-16.770447,"median":-8.515294,"eighty":-2.531958,"marketCap":57469534},{"date":"2024-03-01","current":-2.126077,"twenty":-16.704302,"median":-8.333117,"eighty":-2.50364,"marketCap":57748513},{"date":"2024-03-08","current":-2.314377,"twenty":-16.616611,"median":-8.290129,"eighty":-2.482023,"marketCap":62863115},{"date":"2024-03-15","current":-2.821075,"twenty":-16.559853,"median":-8.227337,"eighty":-2.484293,"marketCap":76626046},{"date":"2024-03-22","current":-2.45817,"twenty":-16.504894,"median":-8.169883,"eighty":-2.484293,"marketCap":66768812},{"date":"2024-03-28","current":-2.643046,"twenty":-16.389693,"median":-8.076394,"eighty":-2.485232,"marketCap":71790422},{"date":"2024-04-05","current":-2.405758,"twenty":-15.948064,"median":-7.968764,"eighty":-2.478712,"marketCap":69930566},{"date":"2024-04-12","current":-1.170887,"twenty":-15.749184,"median":-7.872428,"eighty":-2.477895,"marketCap":34035355},{"date":"2024-04-19","current":-0.895761,"twenty":-15.429079,"median":-7.832767,"eighty":-2.455369,"marketCap":26037977},{"date":"2024-04-26","current":-0.938389,"twenty":-15.339387,"median":-7.81597,"eighty":-2.391538,"marketCap":27277081},{"date":"2024-05-03","current":-1.048407,"twenty":-15.197309,"median":-7.721716,"eighty":-2.342737,"marketCap":30475083},{"date":"2024-05-10","current":-0.98369,"twenty":-15.027656,"median":-7.656232,"eighty":-2.318762,"marketCap":28593905},{"date":"2024-05-17","current":-0.90603,"twenty":-14.795359,"median":-7.610665,"eighty":-2.292536,"marketCap":26336492},{"date":"2024-05-24","current":-0.886421,"twenty":-14.604487,"median":-7.535422,"eighty":-2.26208,"marketCap":25766495},{"date":"2024-05-31","current":-0.948916,"twenty":-14.531446,"median":-7.494663,"eighty":-2.239057,"marketCap":27583083},{"date":"2024-06-07","current":-0.970075,"twenty":-14.326486,"median":-7.40862,"eighty":-2.197974,"marketCap":28198129},{"date":"2024-06-14","current":-1.039667,"twenty":-14.137411,"median":-7.369343,"eighty":-2.115806,"marketCap":30221038},{"date":"2024-06-21","current":-1.062541,"twenty":-14.007811,"median":-7.327858,"eighty":-2.065137,"marketCap":27615452},{"date":"2024-06-28","current":-1.204604,"twenty":-13.78846,"median":-7.297759,"eighty":-2.010359,"marketCap":31307670},{"date":"2024-07-05","current":-1.068083,"twenty":-13.686175,"median":-7.275317,"eighty":-1.965166,"marketCap":27759467},{"date":"2024-07-12","current":-1.140359,"twenty":-13.4847,"median":-7.225933,"eighty":-1.911758,"marketCap":29637927},{"date":"2024-07-15","current":-1.188543,"twenty":-13.480277,"median":-7.22569,"eighty":-1.899433,"marketCap":30890234},{"date":"2024-08-02","current":-1.068083,"twenty":-12.841755,"median":-7.076567,"eighty":-1.873413,"marketCap":27759467},{"date":"2024-08-09","current":-1.01323,"twenty":-12.643221,"median":-7.016084,"eighty":-1.812305,"marketCap":26333856},{"date":"2024-08-16","current":-0.994348,"twenty":-12.560908,"median":-6.91684,"eighty":-1.766596,"marketCap":25843098},{"date":"2024-08-23","current":-1.036532,"twenty":-12.52126,"median":-6.849695,"eighty":-1.758351,"marketCap":26939472},{"date":"2024-08-30","current":-1.000374,"twenty":-12.473063,"median":-6.799492,"eighty":-1.736271,"marketCap":25999723},{"date":"2024-09-06","current":-1.15217,"twenty":-12.364107,"median":-6.617311,"eighty":-1.714074,"marketCap":25686473},{"date":"2024-09-13","current":-1.48939,"twenty":-12.253473,"median":-6.523281,"eighty":-1.688712,"marketCap":33204466},{"date":"2024-09-20","current":-1.405085,"twenty":-12.158042,"median":-6.376534,"eighty":-1.682047,"marketCap":31324968},{"date":"2024-09-27","current":-1.480023,"twenty":-12.045958,"median":-6.294084,"eighty":-1.667461,"marketCap":32995632},{"date":"2024-10-04","current":-1.480023,"twenty":-11.943159,"median":-6.276454,"eighty":-1.655339,"marketCap":32995632},{"date":"2024-10-11","current":-1.430653,"twenty":-11.893709,"median":-6.211978,"eighty":-1.650019,"marketCap":31894986},{"date":"2024-10-18","current":-1.565077,"twenty":-11.8243,"median":-6.129701,"eighty":-1.628561,"marketCap":34891830},{"date":"2024-10-25","current":-1.459458,"twenty":-11.642894,"median":-6.018038,"eighty":-1.618203,"marketCap":32537167},{"date":"2024-10-31","current":-1.325035,"twenty":-11.642894,"median":-5.976572,"eighty":-1.608313,"marketCap":29540322},{"date":"2024-11-08","current":-1.219416,"twenty":-11.643711,"median":-5.888744,"eighty":-1.60059,"marketCap":27185659},{"date":"2024-11-15","current":-1.036984,"twenty":-11.643711,"median":-5.81822,"eighty":-1.590031,"marketCap":23118513},{"date":"2024-11-22","current":-0.807503,"twenty":-11.643711,"median":-5.486121,"eighty":-1.582353,"marketCap":18002472},{"date":"2024-11-29","current":-1.094594,"twenty":-11.643711,"median":-5.397226,"eighty":-1.572515,"marketCap":24402875},{"date":"2024-12-06","current":-1.416956,"twenty":-11.643711,"median":-5.257533,"eighty":-1.561904,"marketCap":26827233},{"date":"2024-12-13","current":-1.405342,"twenty":-11.643711,"median":-5.054343,"eighty":-1.546931,"marketCap":26607338},{"date":"2024-12-20","current":-1.370499,"twenty":-11.607051,"median":-4.90134,"eighty":-1.532584,"marketCap":25947652},{"date":"2024-12-27","current":-1.4518,"twenty":-11.552128,"median":-4.863637,"eighty":-1.513321,"marketCap":27486920},{"date":"2025-01-03","current":-1.440185,"twenty":-11.551659,"median":-4.83536,"eighty":-1.507393,"marketCap":27267024},{"date":"2025-01-10","current":-1.370499,"twenty":-11.551894,"median":-4.778806,"eighty":-1.501215,"marketCap":25947652},{"date":"2025-01-17","current":-1.335656,"twenty":-11.533445,"median":-4.609145,"eighty":-1.488965,"marketCap":25287966},{"date":"2025-01-24","current":-1.382113,"twenty":-11.478602,"median":-4.496037,"eighty":-1.480555,"marketCap":26167547},{"date":"2025-01-31","current":-1.289198,"twenty":-11.469754,"median":-4.439483,"eighty":-1.471957,"marketCap":24408384},{"date":"2025-02-07","current":-1.196283,"twenty":-11.469754,"median":-4.293385,"eighty":-1.469209,"marketCap":22649222},{"date":"2025-02-14","current":-1.207897,"twenty":-11.469754,"median":-4.21798,"eighty":-1.451921,"marketCap":22869117},{"date":"2025-02-21","current":-1.18281,"twenty":-11.449172,"median":-4.115172,"eighty":-1.4518,"marketCap":22394143},{"date":"2025-02-28","current":-1.196283,"twenty":-11.43059,"median":-4.000737,"eighty":-1.440659,"marketCap":22649222},{"date":"2025-03-07","current":-1.335656,"twenty":-11.33139,"median":-3.902221,"eighty":-1.428571,"marketCap":25287966},{"date":"2025-03-14","current":-1.265969,"twenty":-11.33139,"median":-3.760836,"eighty":-1.425853,"marketCap":23968594},{"date":"2025-03-21","current":-1.265969,"twenty":-11.33139,"median":-3.68348,"eighty":-1.414452,"marketCap":23968594},{"date":"2025-03-28","current":-1.173054,"twenty":-11.33139,"median":-3.613584,"eighty":-1.405085,"marketCap":22209431},{"date":"2025-04-04","current":-1.386099,"twenty":-11.33139,"median":-3.424867,"eighty":-1.393728,"marketCap":20810896},{"date":"2025-04-11","current":-1.449241,"twenty":-11.329432,"median":-3.358973,"eighty":-1.393728,"marketCap":21758909},{"date":"2025-04-17","current":-1.354726,"twenty":-11.329432,"median":-3.271534,"eighty":-1.393728,"marketCap":20339850},{"date":"2025-04-25","current":-1.512252,"twenty":-11.33139,"median":-3.219049,"eighty":-1.391372,"marketCap":22704949},{"date":"2025-05-02","current":-1.654025,"twenty":-11.33139,"median":-3.14907,"eighty":-1.391372,"marketCap":24833538},{"date":"2025-05-09","current":-1.638273,"twenty":-11.33139,"median":-3.054422,"eighty":-1.391372,"marketCap":24597028},{"date":"2025-05-16","current":-1.636168,"twenty":-11.33139,"median":-3.009111,"eighty":-1.391372,"marketCap":24565433},{"date":"2025-05-23","current":-1.528308,"twenty":-11.33139,"median":-2.995115,"eighty":-1.391372,"marketCap":22946022},{"date":"2025-05-30","current":-1.489391,"twenty":-11.33139,"median":-2.970548,"eighty":-1.391372,"marketCap":22361722},{"date":"2025-06-06","current":-1.521043,"twenty":-11.33139,"median":-2.94613,"eighty":-1.391372,"marketCap":21790456},{"date":"2025-06-13","current":-1.554109,"twenty":-11.33139,"median":-2.925136,"eighty":-1.391372,"marketCap":22264162},{"date":"2025-06-20","current":-1.727706,"twenty":-11.3448,"median":-2.904177,"eighty":-1.390368,"marketCap":24751116},{"date":"2025-06-27","current":-2.000502,"twenty":-11.249877,"median":-2.87976,"eighty":-1.390368,"marketCap":28659187},{"date":"2025-07-03","current":-1.950902,"twenty":-11.249877,"median":-2.859892,"eighty":-1.390368,"marketCap":27948629},{"date":"2025-07-11","current":-2.215432,"twenty":-11.249877,"median":-2.83188,"eighty":-1.390368,"marketCap":31738273},{"date":"2025-07-18","current":-1.983969,"twenty":-11.249877,"median":-2.814228,"eighty":-1.390368,"marketCap":28422334},{"date":"2025-07-25","current":-1.888077,"twenty":-11.249877,"median":-2.7997,"eighty":-1.390368,"marketCap":27048588},{"date":"2025-08-01","current":-2.463428,"twenty":-11.249877,"median":-2.773956,"eighty":-1.390368,"marketCap":35291065},{"date":"2025-08-08","current":-2.231965,"twenty":-11.249877,"median":-2.760697,"eighty":-1.390368,"marketCap":31975126},{"date":"2025-08-15","current":-2.942887,"twenty":-11.249877,"median":-2.752016,"eighty":-1.390368,"marketCap":42159796},{"date":"2025-08-22","current":-1.702906,"twenty":-11.249877,"median":-2.725685,"eighty":-1.390368,"marketCap":24395837},{"date":"2025-08-29","current":-1.719439,"twenty":-11.249877,"median":-2.677348,"eighty":-1.390368,"marketCap":24632690},{"date":"2025-09-05","current":-1.949029,"twenty":-11.267807,"median":-2.645234,"eighty":-1.389364,"marketCap":25528382},{"date":"2025-09-12","current":-1.949029,"twenty":-11.249877,"median":-2.629144,"eighty":-1.390368,"marketCap":25528382},{"date":"2025-09-19","current":-1.912599,"twenty":-11.249877,"median":-2.60856,"eighty":-1.390368,"marketCap":25051216},{"date":"2025-09-26","current":-1.876168,"twenty":-11.249877,"median":-2.582034,"eighty":-1.390368,"marketCap":24574050},{"date":"2025-10-03","current":-1.894383,"twenty":-11.175595,"median":-2.559317,"eighty":-1.390368,"marketCap":24812633},{"date":"2025-10-10","current":-2.140289,"twenty":-10.945403,"median":-2.535016,"eighty":-1.390368,"marketCap":28033503},{"date":"2025-10-17","current":-1.994567,"twenty":-10.698768,"median":-2.508089,"eighty":-1.390368,"marketCap":26124839},{"date":"2025-10-24","current":-1.956706,"twenty":-10.542917,"median":-2.483752,"eighty":-1.390368,"marketCap":25628938},{"date":"2025-10-31","current":-1.947433,"twenty":-10.473759,"median":-2.468241,"eighty":-1.390368,"marketCap":25507474},{"date":"2025-11-07","current":-1.873245,"twenty":-10.150995,"median":-2.438629,"eighty":-1.390368,"marketCap":24535761},{"date":"2025-11-14","current":-1.836336,"twenty":-9.913182,"median":-2.401527,"eighty":-1.390368,"marketCap":24052333},{"date":"2025-11-21","current":-1.745312,"twenty":-9.648178,"median":-2.35561,"eighty":-1.390368,"marketCap":22167210},{"date":"2025-11-28","current":-1.855099,"twenty":-9.570993,"median":-2.342251,"eighty":-1.390368,"marketCap":23561618},{"date":"2025-12-05","current":-2.218698,"twenty":-8.728408,"median":-2.312467,"eighty":-1.390368,"marketCap":28179686},{"date":"2025-12-12","current":-1.834251,"twenty":-8.41304,"median":-2.297891,"eighty":-1.390368,"marketCap":23296826}],"updateTime":1765770370276},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENLV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586252234","title":"Enlivex Therapeutics Raises $212 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252234","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586252234?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:03","pubTimestamp":1764162221,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the closing of a $212 million private placement. The company plans to use the net proceeds from this unregistered sale of shares to implement the world's first RAIN prediction markets token digital asset treasury strategy, as well as to continue advancing its core business operations, including the clinical development of AllocetraTM for knee osteoarthritis. The private placement also coincided with the appointment of former Italian Prime Minister Matteo Renzi to the company's Board of Directors. BTIG served as the sole placement agent and exclusive financial advisor for the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9qRnVq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","BK4139"],"gpt_icon":0},{"id":"2585980554","title":"Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2585980554","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585980554?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995637,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/11/49030696/nasdaq-surges-350-points-enlivex-therapeutics-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INHD","CVAC","QID","BK4539","QLD","BK4548","CLSD","NVIW.SI","SQQQ","BK4185","BK4007","PMN",".IXIC","TQQQ","CLSDQ","IVP","PCOM","PSQ","BK4122","USAW.SI","USJW.SI","BK4209","BK4139","MNQmain","TSYW.SI","ENLV","BK4006","NQmain","LENZ","BK4551","TWNP"],"gpt_icon":1},{"id":"2585846470","title":"Press Release: Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2585846470","media":"Dow Jones","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585846470?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:55","pubTimestamp":1763988900,"startTime":"0","endTime":"0","summary":"- Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation.- RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation.- Mr. Matteo Renzi, former Prime Minister of Italy, will be appointed to the Enlivex Board of Directors following closing of the private placement.- Price per share of $1.00, representing a premium of 11.5% from previous closing price.\"With the recent institutional interest in leading prediction markets companies -- $2 billion investment by NYSE's parent company in Polymarket, and Kalshi's $300 million financing round led by Andreessen Horowitz  and Sequoia Capital -- it appears that this industry is maturing and has strong growth potential. We believe that following the closing of t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","US10Y.BOND","BK4139","BK4161","BK4539","US6M.BOND","US3Y.BOND","TMF","BK4555","EMA","US7Y.BOND","BK4099","TM","ENLV","TLTW","BK4585","BK4588","PIPE","BK4604","03160","US5Y.BOND","BK4007","RAIN","US12M.BOND","US2Y.BOND","US30Y.BOND"],"gpt_icon":1},{"id":"2585462816","title":"EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462816","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462816?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:46","pubTimestamp":1763988360,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd.  on Monday announced a private investment in public equity of 212 million shares at $1.00 per share, representing a premium of 11.5% from the closing price of the stock on November 21, 2025.The company expects gross proceeds of approximately $212 million .Enlivex will use the proceeds from the PIPE to implement the first RAIN prediction markets token treasury strategy, while continuing its focus on the company's core business operations.RAIN is a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol is fully permissionless, allowing anyone to create and trade custom options on any market.\"We believe that following the closing of this transaction and the implementation of the RAIN treasury strategy, Enlivex will become the first U.S.-traded public company to provide investors with an exposure to prediction markets\", stated Shai Novik, Chairman of the Board of Directors of Enlivex.In the overall modified intention-to-tr","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/24/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/24/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/49027788/exclusive-enlivex-raises-over-200-million-to-launch-first-public-company-prediction-markets-play","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/49027788/exclusive-enlivex-raises-over-200-million-to-launch-first-public-company-prediction-markets-play","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2585916469","title":"Enlivex Reports Six-Month Data Showing Sustained Pain Relief With Allocetra in Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2585916469","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585916469?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:40","pubTimestamp":1763984414,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra trial  in patients with moderate to severe knee osteoarthritis. The results, which have already been presented, indicate that Allocetra demonstrated substantial and durable reduction in pain and improvement in function across multiple efficacy endpoints in patients aged 60 and above, compared to placebo. The six-month data reaffirm findings reported at three months and show a robust positive correlation between patient age and the magnitude of clinical effect. Allocetra maintained a favorable safety profile through the six-month follow-up. Enlivex plans to initiate a Phase IIb trial evaluating Allocetra in age-related primary knee osteoarthritis in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4wMbDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","ENLV","LU2210149790.SGD","NDAQ","BK4588","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2578951834","title":"Enlivex Therapeutics Reports Positive Phase IIa Allocetra Results in Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2578951834","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578951834?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:15","pubTimestamp":1761653717,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. has announced that it will present new clinical data from its Phase IIa trial evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis at the American College of Rheumatology  Convergence 2025, scheduled for October 24-29 in Chicago, Illinois. The late-breaking poster presentation will feature 3-month topline data from the ENX-CL-05-001 study, reporting clinically meaningful and statistically significant improvements in pain reduction and functional outcomes compared to placebo in idiopathic age-related osteoarthritis patients aged 60 and above. The presentation will also include new biomarker data and findings regarding responder populations. Results will be presented by Professor Philip Conaghan on October 28, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLD94W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","ENLV","NDAQ","BK4585","BK4139"],"gpt_icon":0},{"id":"2570444049","title":"Enlivex Therapeutics Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2570444049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570444049?lang=en_us&edition=fundamental","pubTime":"2025-09-26 04:32","pubTimestamp":1758832326,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. has announced that it will hold its Annual General Meeting of Shareholders on November 10, 2025, at its offices in Ness Ziona, Israel. During the meeting, shareholders will vote on the election of Shai Novik, Dr. Roger Pomerantz, Dr. Abraham Havron, Dr. Gili Hart, and Andrew Singer to the Company's Board of Directors, each to serve until the next annual general meeting of shareholders and until their successors are duly elected and qualified. In addition, shareholders will be asked to approve an increase in the Company's authorized share capital and to amend the Company's Articles of Association accordingly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL2Cncpy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","BK4139"],"gpt_icon":0},{"id":"2566999315","title":"Enlivex Therapeutics CEO issues letter to shareholders on Allocetra results","url":"https://stock-news.laohu8.com/highlight/detail?id=2566999315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566999315?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:10","pubTimestamp":1757592659,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics (ENLV) issued the following update to shareholders from Chief Executive Officer, Oren Hershkovitz, highlighting the strength o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-ceo-issues-letter-to-shareholders-on-allocetra-results-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-ceo-issues-letter-to-shareholders-on-allocetra-results-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ","ENLV"],"gpt_icon":0},{"id":"2566998288","title":"Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2566998288","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566998288?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:00","pubTimestamp":1757592038,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra in Knee Osteoarthritis; Plans Phase IIb Trial in 2026. Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra in knee osteoarthritis . The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL2jBvH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","ENLV","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2566789694","title":"Enlivex Therapeutics Ltd. Secures Israeli Patent for Allocetra™ in Osteoarthritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2566789694","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566789694?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:00","pubTimestamp":1757419254,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. has announced the issuance of a new Israeli patent, numbered 290470, titled \"THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS.\" This patent provides intellectual property protection through at least 2040, covering methods of using Allocetra to treat subjects with osteoarthritis. The announcement follows positive data from a Phase IIa clinical trial evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis, showing significant improvements in knee pain and function.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on September 09, 2025, and is solely responsible for the inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL2VgFH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","ENLV","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2563070670","title":"Enlivex Therapeutics Ltd reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2563070670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563070670?lang=en_us&edition=fundamental","pubTime":"2025-08-30 06:25","pubTimestamp":1756506309,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd reports results for the quarter ended June 30 - Earnings SummaryEnlivex Therapeutics Ltd ENLV.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nL8N3UL1F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV"],"gpt_icon":0},{"id":"2563710200","title":"Enlivex Therapeutics Reports Net Loss of $5.32 Million, EPS Declines to $(0.22)","url":"https://stock-news.laohu8.com/highlight/detail?id=2563710200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563710200?lang=en_us&edition=fundamental","pubTime":"2025-08-30 04:17","pubTimestamp":1756498653,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, reported its financial results, showing a net loss of $5.32 million for the period, compared to a net loss of $7.24 million in the prior period. The basic and diluted loss per share was $0.22, an improvement from a loss of $0.38 per share in the previous period. The weighted average number of shares outstanding was 23.81 million, up from 19.13 million previously. The company focuses on developing AllocetraTM, a universal cell therapy designed to reprogram macrophages to their homeostatic state, crucial for rebalancing the immune system and addressing life-threatening conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the origi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL8Mjygm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV"],"gpt_icon":0},{"id":"2561649400","title":"Enlivex Therapeutics Ltd  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2561649400","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561649400?lang=en_us&edition=fundamental","pubTime":"2025-08-23 04:09","pubTimestamp":1755893360,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd  expected to post a loss of16cents a share - Earnings Preview Enlivex Therapeutics Ltd ENLV.OQ, ENLV.O is expected to  show no change in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL8N3UE19V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV"],"gpt_icon":0},{"id":"2560900902","title":"Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2560900902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560900902?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:52","pubTimestamp":1755521520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENLV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 08:52 ET (12:52 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","LENZ"],"gpt_icon":0},{"id":"2560047459","title":"Enlivex Therapeutics Announces Positive Results from Phase I/II Trial of Allocetra™ for Knee Osteoarthritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560047459","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560047459?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:45","pubTimestamp":1755517512,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. has announced positive topline data from the Phase IIa stage of their clinical trial ENX-CL-05-001, which evaluates the efficacy of Allocetra in treating patients with moderate-to-severe knee osteoarthritis. The trial, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled study, demonstrated significant improvements in the treatment arm. In the modified intention-to-treat population, there was a 24% reduction in knee pain and a 26% improvement in knee function. Notably, in age-related primary osteoarthritis patients, a 72% reduction in knee pain and a 95% improvement in knee function were observed compared to placebo. The treatment also exhibited a favorable safety profile with no severe adverse events reported. The results were presented during a webinar held on August 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3K7Zw6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","BK4139","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","ENLV"],"gpt_icon":0},{"id":"2559295206","title":"Enlivex Therapeutics to Present Promising 3-Month Topline Data from Phase IIa Knee Osteoarthritis Trial on August 18 Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2559295206","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559295206?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:42","pubTimestamp":1755175371,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd., a clinical-stage company specializing in macrophage reprogramming immunotherapy, has announced an upcoming presentation of 3-month topline data from its Phase IIa trial evaluating Allocetra in patients with moderate to severe knee osteoarthritis. The data will be discussed during a webinar scheduled for August 18, 2025, at 8:00 AM Eastern Time. This trial, identified as ENX-CL-05-001, is a double-blind, randomized, placebo-controlled study focusing on the safety and efficacy of Allocetra. The study assesses joint pain and function at 3, 6, and 12 months post-injection in comparison to a placebo. To date, 134 patients have completed the 3-month follow-up period, which is the trial's primary timepoint for measuring key endpoints. The presentation aims to provide detailed insights into the interim results and explore potential benefits of expanding the trial's enrollment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL8d4qcC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2554477114","title":"Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2554477114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554477114?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:30","pubTimestamp":1753705816,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra for Knee Osteoarthritis. Enlivex Therapeutics Ltd.  has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra injections, with evaluations set for three, six, and twelve months post-treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLsnbZn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","ENLV","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2542331490","title":"Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542331490","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542331490?lang=en_us&edition=fundamental","pubTime":"2025-06-10 20:32","pubTimestamp":1749558772,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd.  has announced that it will present clinical data from its ongoing study of Allocetra, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology  European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL4N1hkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","ENLV","LU2095319765.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2539085392","title":"Enlivex Therapeutics Ltd. Reports No Revenue, Increased Loss for Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539085392","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539085392?lang=en_us&edition=fundamental","pubTime":"2025-05-31 04:31","pubTimestamp":1748637089,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics Ltd. has released its unaudited financial results for the first quarter ending March 31, 2025. The company reported no revenue for the period, consistent with the same quarter in 2024. The net loss for the quarter was $3.452 million, an improvement from a net loss of $4.140 million in the same period last year. Research and development expenses decreased to $2.550 million from $2.857 million, and general and administrative expenses fell to $954,000 from $1.093 million in the previous year. Enlivex's management and board of directors remain optimistic about the company's financial resources, stating they are sufficient to continue product development for at least the next twelve months. However, the company may seek additional capital within this period. The long-term operational viability of Enlivex is dependent on further financial support and the successful development and revenue generation from its product candidates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL7RBZHl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enlivex Therapeutics Ltd. Reports No Revenue, Increased Loss for Q1 2025","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}